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Glioblastoma is the most common and aggressive adult brain tumour, with
poor median survival and limited treatment options. Following surgical
resection and chemotherapy, recurrence of the disease is inevitable. Genomic
studies have identified key drivers of glioblastoma development, including
amplifications of receptor tyrosine kinases, which drive tumour growth.
To improve treatment, it is crucial to understand survival response processes
in glioblastoma that fuel cell proliferation and promote resistance to treat-
ment. One such process is autophagy, a catabolic pathway that delivers
cellular components sequestered into vesicles for lysosomal degradation.
Autophagy plays an important role in maintaining cellular homeostasis
and is upregulated during stress conditions, such as limited nutrient and
oxygen availability, and in response to anti-cancer therapy. Autophagy
can also regulate pro-growth signalling and metabolic rewiring of cancer
cells in order to support tumour growth. In this review, we will discuss
our current understanding of how autophagy is implicated in glioblastoma
development and survival. When appropriate, we will refer to findings
derived from the role of autophagy in other cancer models and predict the
outcome of manipulating autophagy during glioblastoma treatment.1. Introduction to glioblastoma
Glioblastoma, a grade IV astrocytoma, is themost common and aggressive type of
primary brain tumour in adults. Gene expression analyses of patient-derived
tumour cells revealed three distinct glioblastoma subtypes, classical, proneural
and mesenchymal, which are classified based on their molecular genotypes [1].
Recently, these molecular subtypes have been found to associate with different
cellular states identified by transcriptomic analyses [2]. Neural-progenitor-like
and oligodendrocyte-progenitor-like states are enriched in cells associated with
the proneural molecular subtype, while the astrocyte-like and mesenchymal-like
states coincide with the classical and mesenchymal subtypes, respectively [2].
All molecular subtypes of glioblastoma are driven by the gain-of-function
of receptor tyrosine kinases (RTKs) and/or the loss of tumour suppressor
activities (including PTEN, TP53, NF1 and CDKN2a) [3]. These events lead
to the overactivation of the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K) pathways, which stimulate cell growth
and proliferation. The classical subtype is distinguished by alterations causing
hyperactivation of the RTK EGFR, with the most frequent variation being the
expression of EGFRvIII, a truncated mutant that lacks the extracellular ligand-
binding domain and signals constitutively in the absence of growth factors [3].
In comparison, the overexpression of the RTK PDGFRA is associated with the
proneural subtype, whereas the loss ofNF1 is linked to the mesenchymal subtype
[3]. Nevertheless, cells derived from the same patient can harbour mutations
in multiple RTKs and molecular subtypes [4,5], resulting in intra-tumoural
heterogeneity and decreased patient survival [6].
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2The ability of tumours to switch from one subtype to
another has also been observed in glioblastoma, with the
underlying molecular mechanism largely unknown. Mount-
ing evidence indicates that a pool of glioblastoma stem cells
(GSCs) are a potential causative source [7]. Glioblastoma
tumours contain GSCs that express varying stemness gene
signatures thus providing another layer of inter- and intra-
tumour diversity [8]. GSCs may also contribute to tumour
dormancy, recurrence and resistance to therapy [7].
The current standard of care for glioblastoma patients is
surgical resection followed by treatment with the chemother-
apeutic agent, temozolomide [9,10]. However, the relapse of
glioblastoma tumours is inevitable and treatment resistance
develops such that the median survival of patients from the
time of diagnosis is approximately 15 months. Variations in
median survival exist between patients harbouring a predo-
minant glioblastoma subtype, with mesenchymal tumours
exhibiting the worst prognosis (11.5 months) compared to
classical and proneural tumours (14.7 and 17.0 months,
respectively) [1].
One potential explanation for the molecular subtype-
dependent variation in the survival of glioblastoma
patients is the differences in the tumour immunemicroenviron-
ment. Approximately, one-third of the glioblastoma tumour
mass is composed of innate immune tumour-associated
macrophages (TAMs) that have mostly infiltrated from the
peripheral immune system [11,12]. These TAMs express an
anti-inflammatory ‘M2’ phenotype, which is associated
with tumour cell immune evasion [12,13]. The recruited
macrophages are enriched in the mesenchymal subtype,
in comparison to the proneural and classical subtypes, which
may contribute to the enhanced resistance to treatment
observed in this subclass [1].
Irrespective of the underlying molecular mechanisms
contributing to enhanced patient survival, glioblastoma
remains a cancer of a high mortality rate [14]. The challenge
in treating glioblastoma begins with the inability to surgically
remove the entire tumour mass due to its diffuse nature and
penetration into normal brain tissue. Glioblastoma cells
enriched in mesenchymal subtype markers have the most
invasive phenotype in comparison to the other subtypes
[15]. In addition, acquired resistance to therapy is frequent
and has been attributed to intra-tumoural heterogeneity
and subtype switching upon tumour recurrence, which
occurs in almost 50% of relapsed glioblastoma [1].
The aggressive nature of glioblastoma, including
unconstrained growth, invasion into the normal brain
parenchyma and resistance to therapy, indicates that glio-
blastoma cells have developed mechanisms to survive cell
stress and proliferate under restrictive conditions. It is there-
fore important to understand cellular survival mechanisms
used by glioblastoma cells in order to develop new treat-
ments that can effectively target the tumour. Autophagy is
one such pathway that is upregulated in cancer cells in
response to stress. This review aims to explore what is
known in the literature regarding the role of autophagy
during the development and survival of glioblastoma cells.
When appropriate, we will discuss the role of autophagy in
other cancers and the potential applications to glioblastoma.
However, we will first introduce the current models used to
study glioblastoma and their drawbacks in order to better
grasp the limitations of studying the role of autophagy in
this aggressive cancer.2. Limitations of current models of
glioblastoma
The ideal model of glioblastoma should mimic various
aspects seen in patients including molecular heterogeneity,
interaction with stromal cells, invasion and exposure to
growth restrictive conditions. To date, no individual model
can recapitulate all these aspects. Here, we will briefly outline
the advantages and limitations of the currently available
models to study glioblastoma (recently reviewed in [16]).
2.1. Cell culture models
Cell culture models provide the flexibility to enable in-depth
examination of molecular details and imaging analyses in a
simplified and controlled manner. This comes at a cost of
excluding the contribution of the tumour microenvironment
and the underlying molecular complexity [17]. In addition,
artificially altering metabolic properties by supplementing
growth media with serum, growth factors and excess nutri-
ents are common practices in cell culture models that may
affect various cellular properties [18]. Furthermore, cell line
divergence over time, either through the accumulation of
new mutations or cell type-specific selection, highlights the
need to carefully monitor molecular changes of cultured
cells [16]. This was also shown in some cases whereby the
injection of molecularly defined glioblastoma patient cells
into mice showed divergence from the original molecular
subtype [19], thereby confirming previous findings that
some molecular signatures (such as the proneural subtype)
are more transcriptionally stable [20].
Culture conditions are likely to influence the maintenance
of original cell identity. Recent studies have shown that
culturing glioblastoma patient-derived stem cells under
serum-free stem cell conditions in monolayers is more likely
to preserve long-term stem cell properties in comparison to
cells grown in neurospheres [18,21–23]. Importantly, when
intracranially injected into mice, these GSC lines can form
tumours that are histopathologically similar to glioblastoma
and can therefore be used for drug screening due to their
stability and expandability in culture [23]. Using this mono-
layer culture method, both mouse and human neural stem
cells (NSCs) can be easily manipulated by CRISPR/Cas9
technology to introduce tumour-associated oncogenic
mutations that model glioblastoma [24]. Tumour-initiating
mouse NSCs can be derived and re-implanted in the same
animal species, therefore enabling tumour development in
the context of an intact immune microenvironment.
2.2. Organoids
Three-dimensional organoids are an emerging novel model
system to study glioblastoma. Organoids were initially grown
from dissociated patient-derived GSCs that can infiltrate and
proliferate in human cerebral organoids [25]. However, these
models are labour-intensive and require prolonged periods
to grow. More recently, organoids have been generated by
propagating small sections from whole tumours in a defined
culture media [26]. This is advantageous because undissocia-
ted glioblastoma sections can retain their heterogeneity,
micro-vasculature, certain components of the tumour micro-
environment, and hypoxic gradients [26]. These are attractive
royalsocietypublishing.org/journal/rsob
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3traits that allow the rapid generation of organoids that can be
used for extensive drug screening [17] and testing immu-
notherapies [26]. However, these organoids may not be easily
genetically manipulated, thus limiting their utility.
2.3. Mouse models
Mouse models of glioblastoma provide an important tool
to investigate the role of the tumour microenvironment, the
interaction of tumour cells with stromal cells and the vascula-
ture, and tumour cell invasion into the brain parenchyma.
Brain tumours that resemble glioblastomas can be induced in
mice using genetically engineered mouse models (GEMMs)
or by injecting animals with the tumour-initiating mouse-
or patient-derived cells. The different glioblastoma mouse
models have been comprehensively reviewed in [16].
A well-known GEMM of glioblastoma is the replication-
competent avian sarcoma-leukosis virus LTR splice acceptor/
tumour virus A (RCAS/TVA) model. This model has been
engineered to express the avian virus receptor TVA in glial
progenitor cells in order to allow the delivery of transgenes
upon viral injection [27]. Particular benefits of this model
are examining the mechanism of tumour initiation in an
immune-intact animal as well as the flexibility of modifying
the viral inserts. However, this model is restricted by the
size of the viral cargo [28], an aspect overcome in more
recently developed virally induced glioblastoma models [29].
Additional transgenic glioblastoma models exist but are lim-
ited by the requirement of extensive animal breeding [30,31].
Although GEMMs do not model the genetic heterogeneity
and complexity observed in human tumours, they do provide
insights into the role of the tumour immunemicroenvironment
and interactionwith stromal cells. Parallel studies using human
cells injected into immune-compromised mice or mouse
cells in syngeneic immune-competent animals are likely to
provide a more comprehensive picture into the complexity of
glioblastoma growth and response to treatment.3. Overview of autophagy
3.1. Proteins involved in the autophagy pathway
Autophagy is a catabolic process that involves the engulfment
of cytoplasmic components in double-membrane vesicles,
called autophagosomes, which can fuse with lysosomes for
the degradation and recycling of their contents to provide
metabolic substrates. Autophagy occurs constitutively in cells
at basal levels to maintain homeostasis through the turnover
of damaged organelles and unwanted cellular material [32].
In periods of cell stress, such as nutrient starvation, hypoxia,
DNA damage and pathogen infection, autophagy is upregu-
lated in order to allow cells to adapt to the environmental
changes and restore cell function [32].
Several autophagy-related (ATG) protein complexes are
required for autophagosome biogenesis. The activation of
the Unc-51-like kinase 1 (ULK1) complex can initiate auto-
phagy during periods of nutrient and energy depletion. This
can occur upon the inactivation of the mammalian target of
rapamycin (mTOR) complex 1 (mTORC1) in response to low
nutrient levels or activation of the AMP-activated protein
kinase (AMPK) in response to energy depletion [33].
The ULK1 complex subsequently triggers the activity of thePI3K class III-complex 1 (PI3KC3-C1) containing ATG14L1,
Beclin 1, Vps34 and p150, which is required to generate
PI(3)P on the growing autophagosomal membrane [32]. The
elongation and maturation of the autophagosome require the
lipid conjugation of ATG8 protein family members (including
the microtubule-associated protein 1A light chain 3 (LC3)
subfamily members LC3A, LC3B and LC3C) on autophagoso-
mal double membranes [34]. Autophagosome maturation is
required for their efficient fusion with lysosomes and
relies on the activities of ATG7, ATG3 and the ATG16L1-
ATG5-ATG12 complex [34]. The degradation products are
then recycled back to the cell, thus providing essential nutrients
and energy supply to support cell growth (figure 1).
Knockout of core Atg genes in mice results in the loss of
neonatal survival thereby revealing a vital role for autophagy
during mammalian development [35]. Interestingly, the
neonatal lethality in Atg5-deficient mice is rescued by re-
expressing Atg5 in neurons, indicating that autophagy plays
an essential role in brain development [36]. Whole-body inhi-
bition of autophagy in adult animals or neuron-specific
deletion of Atg5 or Atg7 also resulted in neurodegeneration
phenotypes in mice, further highlighting the role of auto-
phagy in maintaining neuronal homeostasis [37–39]. The
underlying mechanism for the role of autophagy in neurons
is largely unknown but is probably related to its role in clear-
ing protein aggregates. Autophagy is also involved in
maintaining the function of various organs whereby mice
with genetic inhibition of autophagy throughout the body,
excluding the brain, also exhibited failure of various organs,
ageing phenotypes and reduced lifespan [36,40]. While a cru-
cial function for autophagy has been described in
maintaining the health of the nervous system and various
organs, its role during the development of cancers within
the nervous system remains a largely unexplored area.
Unlike the neonatal lethality phenotype observed upon
the knockout of core Atg genes in mice, the knockout of
some autophagy players results in embryonic lethality
[41–43]. This suggests that, in addition to their role in canoni-
cal autophagy (described above), these genes potentially have
other functions. Of these gene products, Beclin 1 has been
shown to play an additional role in endocytic trafficking by
forming part of the PI3KC3 complex 2 (PI3KC3-C2) along
with UVRAG, Vps34 and p150 [44,45]. Beclin 1 has been
frequently associated with the development of various can-
cers [41,46]. However, whether the tumour-suppressive
activities of Beclin 1 require its autophagic or endocytic
functions remain to be further explored.
Several ATGproteins, includingATG3, ATG5 andATG7, are
also required for lipidation of ATG8 family members on single-
membrane vesicles, such as phagosomes and perturbed endo-
somes. The functional relevance of this non-canonical ATG8
lipidation on single-membrane vesicles may be distinct from
its role during autophagosome biogenesis and can be triggered
by various stimuli, including pathogen infection and treatment
with lysosomotropic agents [47–49]. This suggests that inhibiting
the activities of core autophagyplayersmayaffect additional cel-
lular processes. Therefore, the interpretation of the commonly
used autophagy assays relying on ATG8 lipidation (especially
duringdrug treatment)may require careful investigations. Inter-
estingly, certain ATG complexes, such as the ULK1 complex, are
dispensable for the non-canonical lipidation of ATG8 proteins
andmay be used as tools to distinguish canonical (double-mem-
brane) from non-canonical (single-membrane) ATG8 lipidation.
ATG3, ATG7, ATG5,
ATG12, ATG16L1
cargo
(e.g. damaged
proteins and
organelles)
recycling of
macromolecules
(e.g. amino acids,
fatty acids and sugars)
knockout/knockdown
of ATG genes
LC3-ILC3 LC3-II
CQ
HCQ
BafA13-MA
lysosome
phagophore
ULK1 complex
PI3KC3 complex 1
autophagosome autolysosome
autophagy-inducing signals
DNA damage (e.g. chemotherapy), hypoxia,
nutrient depletion and RTK inhibition
ATG4
rapamycin RTK signallingmTORC1
Figure 1. Schematic depicting an overview of the autophagy pathway and mechanisms used to manipulate autophagy. Activation of autophagy occurs upon the
inhibition of the mammalian target of rapamycin (mTORC1) in response to cell stress signals, such as low nutrient supply and genotoxic stress. Autophagy activation
can be achieved by mTORC1 inhibition by rapamycin or receptor tyrosine kinase (RTK) inhibition. This initiates a cascade of ATG protein complexes, beginning with
the activation of the ULK1 and PI3KC3-C1 complexes and phagophore formation. PI3KC3-C1 activity can be chemically inhibited by 3-methyladenine (3-MA).
Elongation and closure of the phagophore results in autophagosome maturation and requires core ATG proteins, including ATG3, ATG4, ATG7, ATG5, ATG12 and
ATG16L1, that can be genetically targeted to impede this maturation step. The final stage of the pathway involves the fusion of autophagosomes with lysosomes
forming autolysosomes and resulting in the degradation of the cellular cargo by lysosomal hydrolases. The degradation products (including amino acids, fatty acids
and sugars) are recycled and can be used to supply cellular metabolic needs. Chloroquine (CQ), hydroxychloroquine (HCQ) and bafilomycin A1 (BafA1) are chemical
inhibitors of lysosomal acidification that consequently block autophagic flux and lead to the accumulation of autophagosomes in cells.
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43.2. Monitoring autophagy and chemical
modulators
Assays to monitor autophagy mainly rely on measuring
protein levels and modifications as well as cellular localization
[50]. These assays should factor in the dynamic nature of
autophagy that involves the initial formation of vesicles
followed by the degradation of their contents, both steps
being crucial for the completion of autophagic flux. The two
most commonly used markers to monitor autophagy are p62,
a ubiquitin-binding protein that targets cellular cargo to autop-
hagosomes, and membrane-bound lipidated LC3 (LC3-II),
which forms following the lipidation of cytosolic LC3 (LC3-
I). Reduced or increased p62 levels are indicative of high or
low autophagy levels, respectively. On the other hand, autop-
hagy induction stimulates the formation of LC3-II (separated
from LC3-I by a change in migration on SDS-PAGE or by cyto-
plasmic puncta formation) which is eventually degraded by
the action of lysosomal hydrolases. Reduced LC3-II levels
can indicate enhanced autophagic activity resulting in acceler-
ated lysosomal degradation, but it may also correspond to
reduced autophagosome formation and lipidation. Conversely,
enhanced LC3-II protein levels could imply an increase in
autophagosome biogenesis, or it may be indicative of a block
in autophagosome-lysosome fusion.
To accurately measure autophagic flux, careful assays are
required to induce autophagy and concurrently block the
degradation step. Autophagy can be stimulated following
mTORC1 inhibition by nutrient starvation or with chemical
agents such as rapamycin, while blocking the lysosomaldegradation of autophagosome contents is achieved using
inhibitors of lysosomal acidification, such as bafilomycin A1
[51] and chloroquine (CQ) [52] (figure 1). The absence or
increased accumulation of LC3-II in this setting is indicative
of low or high autophagy levels, respectively. This flux
assay can be used to determine autophagy inhibition by
genetic or chemical targeting. Interestingly, CQ has been
used in the clinic for over 50 years as a treatment of malaria
while its less toxic derivative hydroxychloroquine (HCQ) is
used in the treatment of the autoimmune diseases rheuma-
toid arthritis and systemic lupus erythematosus [53].
In addition, both CQ and HCQ can induce ATG8 lipidation
on single membranes [48]. The contribution of this non-
canonical autophagy activation or inhibition of lysosomal
degradation during the therapeutic response to these drugs
remains to be elucidated. Unlike CQ treatment, which inhi-
bits later stages of autophagy by targeting lysosomal
degradation [53], chemical inhibition of early stages of
autophagy can be achieved using the Vps34 inhibitor
3-methyladenine (3-MA) or ULK1 kinase inhibitors, although
toxic effects have been reported due to their modulation of
additional pathways [54].
Given the dynamic nature of autophagosome biogenesis,
it is challenging to measure autophagy in vivo and in human
patients. RNA expression of ATG genes has also been exten-
sively used as a readout for autophagy, but changes in
transcription or protein levels do not necessarily reflect altera-
tions in ATG protein activity. As a result, additional readouts
for autophagy, such as post-translational modifications of
ATG proteins [55], are needed to provide more reliable assess-
ments of autophagic activity.
royalsocietypublishing.org/journal/rsob
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54. Brief overview of the involvement of
autophagy in cancer
Autophagy has fundamental roles in maintaining cell health.
In terms of oncogenic transformation, autophagy can play a
role in preventing oxidative stress and subsequently DNA
damage and cell transformation. This tumour-suppressive
role of autophagy is supported by early studies that
showed increased development of spontaneous, potentially
benign, lung and liver tumours and lymphomas in mice
deleted of autophagy genes Beclin 1, Atg7 and Atg5
[41,46,56]. Interestingly, a reversible RNAi mouse model
that targets Atg5 expression showed that, while extended
autophagy inhibition can accelerate ageing, reactivating
autophagy after a period of inhibition can cause increased fre-
quency of spontaneous tumour development [40]. This
suggests that while autophagy functions in preventing
tumour-inducing cell damage, it may also have a role in
promoting tumour growth [40]. Indeed, there is mounting
evidence indicating that autophagy can affect various aspects
of cancer cell growth including metabolic supply, immune
evasion and response to treatment [57]. How autophagy
can implicate the development and survival of brain tumours
are still areas of open research where predictions can be
drawn based on studies modelling various types of cancers.
Many solid tumours undergo metabolic rewiring to enable
their unconstrained growth in nutrient-deprived microenvir-
onments [58]. Recycling of cellular components (including
amino acids, fatty acids and glucose) upon lysosomal degra-
dation during autophagic flux has been shown to supply the
metabolic demand of oncogenic KRAS- and BRAF-driven
lung tumours [59–62]. In addition, the selective degradation
of defective mitochondria by autophagy (a process known as
mitophagy) might play a vital role in maintaining mitochon-
drial metabolism in cancer cells and support cell growth [60].
Mouse models of melanoma and pancreatic ductal adenocarci-
noma (PDAC) have demonstrated that autophagy activation
in stromal cells can also contribute to tumour growth by
supplying metabolic substrates [63,64].
The role of autophagy during cancer treatment has been
extensively studied using both animal models and cultured
cells. Autophagy can be induced by a wide range of anti-
cancer drug treatments. This can occur directly, for example,
following mTORC1 inhibition by rapamycin [65], or release
of Beclin 1 from negative regulation by EGFR using tyrosine
kinase inhibitors, such as erlotinib [66]. Alternatively, auto-
phagy may be indirectly activated by drug treatment in
response to DNA damaging agents [67], or changes in metab-
olism (as seen following selective pharmacological inhibition
of ERK in PDAC cell lines) [68]. In both cases, it is widely
accepted that autophagy can help support tumour cell survi-
val during therapy with the underlying mechanism being
largely unknown and probably context dependent. In some
cases, however, autophagy has been suggested to exhibit a
cell death-promoting property. It is possible that the delicate
balance between cell survival and death could be tipped by
autophagy overactivation as a last desperate attempt to sur-
vive causing unendurable digestion of cytoplasmic proteins
and organelles [69]. Indeed, the presence of autophagic struc-
tures in dying cells has been noted for many years, hence
the emergence of the concept ‘death with autophagy’. Yet,
although there is evidence demonstrating that autophagycan enhance the effect of some cancer drugs, autophagy upre-
gulation in response to tumour therapies is mostly thought to
be protective to tumour cells, favouring their survival and
thus promoting treatment resistance [67].
Based on promising findings from pre-clinical studies,
several clinical trials have been initiated to investigate the
effect of concurrently inhibiting autophagy during cancer
treatment [70]. Blocking the last stage of the autophagy path-
way using CQ or HCQ is currently the only approved
mechanism of inhibiting autophagy in humans [70]. This
strategy has been shown to be effective in overcoming
resistance to the BRAFV600E kinase inhibitor (vemurafenib)
and restoring its efficacy in treating BRAFV600E-driven brain
tumours [71,72]. More recently, pre-clinical studies demon-
strated that autophagy inhibition sensitizes KRAS-driven
PDAC to pharmacological suppression of the RAS/RAF/
MEK/ERK signalling pathways [68,73] and have paved the
way for a clinical trial examining the combined treatment
with HCQ and the MEK1/2 inhibitor trametinib in PDAC
patients [74].
Overall, the role of autophagy in cancer ismultifarious, vary-
ing from being a tumour suppressingmechanism to supporting
tumour growth and survival. This may reflect tumour type-
and stage-specific functions of autophagy or diverse effects of
inhibiting early stages versus late stages of the pathway (for
example, Vps34 inhibitors versus lysosomal inhibitors). Interest-
ingly, an oncogene-dependent effect of autophagy during
tumour growth has been described in KRASG12D-driven PDAC
and non-small cell lung carcinoma (NSCLC) models, whereby
autophagy loss reduced tumour growth but not when p53 was
additionally deleted [59,75]. Altogether, various considerations
are required when studying the role of autophagy in cancer,
including theuseofmodel systemsandoncogenic combinations,
the specificity of autophagy regulators and the use of reliable
readouts to measure autophagic activities.5. Modelling the role of autophagy in
glioblastoma development
The relevance of autophagy in glioblastoma is not fully
uncovered. The properties of this invasive and resistant
solid tumour could suggest a likely role for autophagy in pro-
moting its growth (figure 2). Here, we will discuss published
findings that are suggestive of the role of autophagy in
glioblastoma survival.
5.1. Transcriptional evidence from glioblastoma patients
Assessing autophagy levels is one approach to examine its
involvement in glioblastoma development. Enhanced auto-
phagic activity evaluated by immunohistochemistry analyses
of resected tumours has been shown to correlate with reduced
glioblastoma patient survival [76,77]. Similarly, autophagy
gene expression profiles in publicly available glioblastoma
datasets show that the mesenchymal subclass exhibited
increased ATG gene transcription, including ATG7, LC3B,
LC3C, ATG16L1 and SQSTM1 (which encodes p62) [78]. In
addition, genes that have been shown to induce autophagy,
such as the p53-target, damage regulated autophagy modu-
lator (DRAM), were also increased [78]. Interestingly, two
recent studies have highlighted an association between high
ATG gene expression signatures and reduced overall survival
treatment resistance unconstrained growth
tumour cell invasionimmune evasion
autophagy: autophagy:
autophagy:autophagy:
• degrades MHC-I
• (non-canonical) induces
   T cell tolerance
• stimulates immunogenic
   cell death
glioblastoma stem cell invasive glioblastoma cell CD4+ T cell chemotherapy/radiotherapy
monoclonal antibody therapyCD8+ T celltumour-associated macrophageglioblastoma cell
• promotes GSC survival • regulates RTK growth
  signalling and endocytic
  trafficking
• enables metabolic rewiring
• impairs EMT-like processes
• downregulates Met
  signalling
• overactivation induces cell
   death
Figure 2. The potential relevance of autophagy in glioblastoma development and survival. Based on what is known from other solid tumour models and from
findings in glioblastoma research, autophagy could be implicated in promoting (green text) or suppressing (purple text) various aspects of glioblastoma progression.
Autophagy may support tumour growth by regulating receptor tyrosine kinase (RTK) signalling and trafficking, in addition to providing metabolites to fuel uncon-
strained proliferation. Autophagy may play a role in tumour cell invasion by regulating the epithelial-to-mesenchymal transition (EMT)-like process and limiting
oncogenic Met signalling. Tumour cell immune evasion can be mediated by the degradation of major histocompatibility complex I (MHC-I) by autophagy, and
immunosuppressive engulfment of dying tumour cells by non-canonical autophagy. By contrast, autophagy activation in dying tumour cells can stimulate immunity
by releasing inflammatory signals. Upregulation of autophagy in response to treatment can support glioblastoma stem cell (GSC) survival while its overactivation
potentially leads to tumour cell death.
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6predominantly in patients with the mesenchymal subtype
[79,80]. This is consistent with the mesenchymal subtype
exhibiting worst patient prognosis [1]. Altogether, these
findings suggest a correlation between enhanced ATG gene
expression and a worse outcome for glioblastoma patients,
thereby suggesting a potential role for autophagy in promoting
glioblastoma growth.
5.2. Evidence from mouse models
As discussed previously, autophagy activation can impact
tumour cells at various stages, including initiation, proliferation
and response to treatment. A limited number of studies have
examined how autophagy influences the formation of glioblas-
toma (table 1). An investigation modelling tumour initiation
in mice demonstrated that, in the absence of autophagy,
glioblastoma development is impeded [81]. This was achieved
using the RCAS/TVA GEMM of glioblastoma induced by
overexpressing KRASG12D in a Cdkn2a−/− background where
autophagy was disrupted by genetic knockdown of Atg7,
Atg13 or Ulk1 in tumour cells [81]. The molecular mechanisms
underlying the requirement of autophagy in this GEMM
remain unclear. Examination of KRASG12D-expressing
Cdkn2a−/− glial cells in culture revealed that autophagy inhi-
bition impaired anchorage-independent cell growth and
induced senescence [81]. This model serves as a starting point
to study autophagy in glioblastoma development as mutations
in the RAS oncogene are only rarely detected in glioblastoma.
Further GEMM studies using established glioblastoma onco-
genic drivers are thus required to confirm the role of
autophagy in initiating tumour development.Autophagy can also implicate tumour cell proliferation.
Orthotopic xenograft experiments of patient-derived GSCs
in immunocompromised mice suggest a link between autop-
hagy and levels of MST4 [82], a serine/threonine kinase that
promotes cell growth and malignant transformation through
activating ERK signalling [83]. ATG4B, one of four ATG4 iso-
forms required for the lipidation and delipidation of ATG8
proteins [34], is activated following its phosphorylation by
MST4 [82]. Knocking down ATG4B impeded the growth
of GSCs expressing high but not low MST4 levels [82].
It may be possible that GSCs with low MST4 expression
are ATG4 independent due to potential compensation by
other ATG4 isoforms supporting the processing of alternative
ATG8 family members [84]. Interestingly, the high expression
levels of MST4 and ATG4B transcripts correlated with GSCs
encompassing the mesenchymal-like molecular subtype and
reduced patient survival [78,82], suggesting a potential mol-
ecular subtype-dependent role of autophagy in regulating
glioblastoma cell growth.
Additionally, EGFRvIII-expressing glioblastoma cells,
which are enriched in the classical subtype, have a greater
dependency on autophagy for growth and survival during
times of metabolic stress induced by nutrient-deprivation
and hypoxia [85]. Non-specific autophagy inhibition by
CQ treatment impaired EGFRvIII tumour growth in a
heterotopic mouse model [85]. This was further translated
to enhanced survival in CQ-treated patients with EGFRvIII-
positive tumours compared to those expressing wild-type
EGFR [85]. Altogether, these findings suggest a potential
oncogene-dependent role of autophagy in promoting
glioblastoma growth.
Table 1. Genetic inhibition of autophagy impairs glioblastoma development in mice (genetically engineered mouse model, GEMM; glioblastoma stem cells,
GSCs).
model autophagy inhibition effects on tumour development reference
RCAS/TVA GEMM (KRASG12D, Cdkn2a−/−) shRNA targeting: Atg7, Atg13, Ulk1 impeded tumour initiation [81]
patient-derived GSCs xenograft shRNA targeting: ATG4B impaired tumour growth by GSCs
expressing high MST4 levels
[82]
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76. Autophagy in the tumour immune
response
The interactions between glioblastoma and immune cells
in the tumour microenvironment may have profound effects
in determining treatment outcome. Manipulating autophagy
has been described to be favourable in the context of immuno-
therapy, which includes dendritic cell (DC) vaccines, chimeric
antigen receptor (CAR)-T cells and immune checkpoint
inhibitors [86]. However, targeting autophagy during immu-
notherapy treatment in glioblastoma has not been studied.
A pre-clinical glioblastoma study showed improved survival
of mice following DC vaccination in combination with
hypericin-based photodynamic therapy-induced immunogenic
cell death [87]. Intriguingly, an autologous DC vaccination
phase I clinical trial extended survival of glioblastoma patients
by enhancing CD8+ T cell infiltration [88]. This improved survi-
val was more prominent in patients predominantly harbouring
themesenchymalmolecular subtype compared to thosewith the
proneural subtype [88]. Since autophagy appears to be elevated
in mesenchymal tumours (discussed above) and it can augment
the immunogenicity of dying tumours by enhancing the release
of the immunostimulatory signals (including calreticulin,
HMGB1 and ATP) [89], it would be interesting to assess the
contribution of autophagy activation in glioblastoma tumour
cells in response to DC vaccination.
By contrast, autophagy may facilitate immune evasion, for
example by degrading major histocompatibility complex
(MHC)-I in tumour cells thereby reducing antigen presentation
and CD8+ T cell recognition, as seen in PDAC [90]. Addition-
ally, inhibiting autophagy by genetic or chemical inhibition
of Vps34 in melanoma and colorectal cancer cells has been
shown to promote their clearance in mouse models by trigger-
ing infiltration of inflammatory immune cells [91]. This
enhanced the efficacy of immune checkpoint inhibitors target-
ingprogrammeddeath 1 (PD-1) andprogrammeddeath ligand
1 (PD-L1) [91]. It is therefore of interest to determine if autop-
hagy inhibition can improve the outcome of recent PD-1/
PD-L1 immunotherapy trials in glioblastoma patients [92–94].
Autophagy proteins not only play a role in the tumour cells
themselves, but their function in immune cells can also contrib-
ute to the outcome of anti-tumour immune responses. The
non-canonical lipidation of ATG8 proteins on single mem-
branes is required in Lewis lung carcinoma myeloid cells to
impair the local anti-tumour T cell activation in response to
the engulfment of dying cells [95]. MHC-II antigen presentation
by DC has also been shown to depend on non-canonical autop-
hagy [49]. It remains to be investigated whether glioblastoma
TAMs and DCs also use non-canonical ATG8 lipidation to
deploy their inhibitory effects on anti-tumour T cells and
promote tumour growth and invasion.Further investigation and pre-clinical models are necess-
ary to discover the role of autophagy in immune responses
associated with glioblastoma and to distinguish the contri-
bution of canonical versus non-canonical lipidation of ATG8
proteins. Particular care should be taken when considering
if autophagy inhibition or activation will potentiate the
immune response to target glioblastoma since the outcome
may vary depending on if autophagy is manipulated in the
tumour and/or immune cells.7. Autophagy and glioblastoma invasion
The invasive nature of glioblastoma cells permits their infil-
tration to the surrounding normal brain tissue and hinders
complete surgical removal. Tumour cells can acquire invasive
properties by undergoing an epithelial-to-mesenchymal tran-
sition (EMT), a reversible process whereby cells lose epithelial
cell properties and gain mesenchymal migratory charac-
teristics. This process involves cytoskeletal remodelling, the
loss of cell-cell adhesions and the degradation of the base-
ment membrane and ECM [96]. EMT is transcriptionally
regulated by the SNAIL family (SNAIL and SLUG), ZEB1
and ZEB2, and TWIST1. These transcription factors are acti-
vated by hypoxia as well as transforming growth factor-β
(TGF-β) and RTK signalling pathways [96]. A characteristic
of EMT is the downregulation of epithelial tight junction
adhesion proteins, such as E-cadherin, followed by enhanced
expression of mesenchymal markers including N-cadherin.
This in turn stimulates Wnt signalling and the nuclear
accumulation of β-catenin that activates the transcription of
genes involved in proliferation and migration [97]. Intri-
guingly, glioblastoma cells have been found to activate an
EMT-like programme [98]. In comparison to other malignant
cells, the membrane localization of N-cadherin, rather than its
expression, is reported to alter glioblastoma cell invasion [99].
Furthermore, reducing N-cadherin levels in glioblastoma
cells has been shown to impair their focal adhesions and
enhance their migratory capacity [100].
Autophagy has been shown to facilitate the degradation of
SNAIL and SLUG in glioblastoma cells thereby consequently
upregulating N-cadherin [101]. This suggests that autophagy
may suppress glioblastoma invasive properties [100,102].
Furthermore, the Wnt pathway is particularly upregulated in
a population of fast-growing, self-renewing proneural-like
GSCs [103]. Autophagy has been previously shown to
impede Wnt signalling by degrading a key component of the
signalling cascade, Dishevelled [104]. Through thismechanism
of Wnt signalling suppression, autophagy activation in glio-
blastoma cell lines can cause the relocalization of β-catenin to
plasma membrane regions associated with N-cadherin [105].
These inhibitory functions of autophagy in glioblastoma
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8invasion are further supported by the finding that auto-
phagy stimulation by mTORC1 inactivation impaired the
migration and invasion of patient-derived glioblastoma cells
in culture [101].
Potential contradicting evidence exists that suggests the
role of autophagy in supporting tumour cell motility and inva-
sion [57]. Downregulating the autophagy players DRAM1,
SQSTM1 and ATG7 impaired the capacity of patient-derived,
mesenchymal-likeGSCs to invade using a transwell cell culture
system, supporting a role for autophagy in glioblastoma inva-
sion [78]. In addition, autophagy has been documented to
regulate oncogenic signalling of the RTK Met [106] which is
amplified in approximately 4% of glioblastoma patients [107]
and is associated with the invasive mesenchymal subtype [3].
In a xenograft mouse model of GSCs, Met overexpression
was shown to support tumour invasion and resistance to
monoclonal antibodies targeting the anti-vascular endothelial
growth factor (VEGF) [108]. Activation of Met upon binding
to its ligand, hepatocyte growth factor (HGF), can drive
EMT and tumour metastasis [109]. Interestingly, optimal Met
signalling requires non-canonical ATG8 lipidation on single
membranes in various cancer lines [106]. On the other hand,
autophagy may also suppress Met signalling by targeting
its degradation through binding with LC3C in breast and
cervical cancer cell lines [110]. HIF2α stabilization can reduce
LC3C expression [111]; therefore, it could be hypothesized
that enhanced expression of HIF in hypoxic tumours, such as
glioblastoma, could releaseMet from LC3C-mediated downre-
gulation [110]. Given that autophagy can both stimulate and
inhibit Met signalling in various cancer cell lines, it would be
interesting to determine how this regulatory network can
implicate invasion of Met-expressing glioblastoma cells.
Overall, these studies suggest a role of autophagy in
regulating glioblastoma invasion. However, it is important to
take into account the effects of the tumour–stroma interactions
and the tumour microenvironment (such as oxygen and nutri-
ent availability) which can affect cell invasion [112]. More
in-depth examination and the development of appropriate
mouse models are therefore required in order to clarify the
function of autophagy in the invasion of glioblastoma into
the brain parenchyma.8. Autophagy proteins facilitate receptor
tyrosine kinase signalling
Inhibiting the RTK signal transduction pathways, which drive
glioblastoma progression, is an attractive therapeutic strategy.
Nevertheless, phase II clinical trials targetingRTKs, forexample,
tyrosine kinase inhibition of EGFR/EGFRvIII or PDGFRα/β,
have failed to significantly improve patient survival compared
to temozolomide or irradiation alone [113,114]. The ineffective-
ness of small molecule inhibitors and antibodies targeting
RTKs potentially occurs due to the development of various
resistance mechanisms [115]. Therefore, finding alternative
ways to clinically manipulate RTK signalling is required.
Accumulating evidence suggest an interaction between
RTK signalling and autophagy [116]. Autophagy players
can facilitate RTK signalling thereby potentially supporting
the development of glioblastoma tumours that rely on RTK
activation [106,117,118]. On the other hand, RTK signalling
can suppress autophagy [66] and their chemical inhibition
is widely known to activate autophagy in cells [116]. Giventhat RTK signalling is elevated in glioblastoma cells, it
remains to be addressed how autophagy may still be active
to support cell growth in the absence of RTK antagonists.
RTKs, such as EGFR, are activated upon binding to their
ligands when located on the plasma membrane and continue
to signal following endocytosis. Signalling from endocytosed
RTKs can be either terminated upon targeting to lysosomes
or maintained upon recycling back to the plasma membrane.
Autophagy can regulate RTK signalling throughvariousmech-
anisms. The loss of autophagy in immortalized glial cells has
been shown to disrupt endosomal homeostasis, consequently
perturbing EGFR trafficking and signalling in response to
growth factor stimulation thereby reducing cell survival
[117]. This was bypassed by EGFRvIII overexpression [117],
with the difference in autophagy dependency likely to reflect
its altered intracellular trafficking compared to wild-type
EGFR [119]. Autophagic membranes can also be used as plat-
forms to enhance MAPK signalling in response to EGFR
stimulation [118] as has been shown with Met signalling
[106]. In these settings, it would be interesting to test whether
treatment with CQ/HCQ can affect EGF-induced signalling
as inhibiting lysosomal activity does not disturb autophagic
membrane formation and may stabilize EGFR.
While trafficking and signalling of EGFR is well studied
thereby facilitating our understanding of its interplay with
autophagy, PDGFR activation (associated with the proneural
subtype) is less well understood. It remains unknown whether
autophagy proteins play a regulatory role in PDGFR signalling
and trafficking. Unlike autophagy inhibition by EGFR acti-
vation, autocrine PDGFRβ signalling has been shown to
enhance autophagy via stabilization of HIF1α during hypoxia
[120], demonstrating a cross-talk between these pathways.
Considering PDGFRα amplification is associated with 13.1%
of glioblastomas [3], it would be beneficial to dissect how
this receptor is regulated and whether inhibiting autophagy
can suppress its activities.9. Autophagy upregulation and resistance
of glioblastoma cells to treatment
Glioblastoma tumours inevitably relapse and are resistant
to temozolomide and radiotherapy treatment. To date, alterna-
tive strategies designed to suppress glioblastoma tumour cell
growth have been unsuccessful. The reasons behind this
include failure to target quiescent tumour-initiating GSCs,
inherent plasticity of tumour cells, reduced drug delivery
across the blood–brain barrier (BBB), and the lack of pre-clinical
studies that model the complex interactions of glioblastoma
tumour cells with the tumour microenvironment.
Quiescent stem cells are resistant to anti-cancer treatment
that target actively proliferating cells by triggering cell death
or inhibiting cell cycle progression. GSC heterogeneity and
plasticity have contributed to the difficulty in translating
drug responses observed in pre-clinical studies [2,8], which
can potentially be resolved by the emerging new glio-
blastoma models [26]. These persistent GSCs can repopulate
the tumour and result in relapse [7,121]. The recurring
tumour exhibits reduced response to treatment potentially
due to mechanisms like chemotherapy-induced hypermuta-
tion providing a selection pressure to favour the growth of
resistant cells [121] or by upregulating survival mechanisms
such as autophagy.
Table 2. The effect of targeting autophagy on glioblastoma survival in response to treatment (3-methyladenine, 3-MA; bafilomycin A1, BafA1; Beclin 1, BECN1;
chloroquine, CQ; hydroxychloroquine, HCQ; suberoylanilide hydroxamic acid, SAHA; temozolomide, TMZ; tyrosine kinase inhibitor, TKI).
treatment autophagy modulator treatment outcome references
clinical trials
surgery + chemotherapy + radiotherapy CQ prolonged patient survival [131,132]
surgery + chemotherapy + radiotherapy HCQ no survival advantage [133]
recurrent glioblastoma following surgery +
chemotherapy + radiotherapy
rapamycin/sirolimus (mTOR inhibitor) no survival advantage [134]
recurrent glioblastoma following surgery +
chemotherapy + radiotherapy
Rapamycin/sirolimus (mTOR inhibitor) +
Erlotinib (EGFR TKI)
no survival advantage [135]
recurrent glioblastoma following surgery +
chemotherapy + radiotherapy
everolimus (sirolimus derivative) +
Gefitinib (EGFR TKI)
no survival advantage [136]
mouse models
TMZ or SAHA CQ reduced tumour volume [128]
ZD6474/vandetanib (multi TKI) CQ reduced subcutaneous
tumour volume
[123]
cell culture
TMZ 3-MA promoted cell viability [126]
BafA1 enhanced cytotoxicity
imatinib (PDGFRα/β, c-abl, and c-kit TKI) siATG5 / 3-MA promoted cell viability [124]
BafA1 enhanced cytotoxicity
ZD6474/vandetanib (multi TKI) shATG7 / shBECN1 / CQ / 3-MA enhanced cytotoxicity [123]
SAHA rapamycin improved cell viability [129]
shLC3A / shBECN1 / shATG5 / BafA1 / CQ enhanced cytotoxicity
SAHA shATG7 enhanced cytotoxicity [130]
royalsocietypublishing.org/journal/rsob
Open
Biol.10:200184
9In addition to supporting the development of glioblastoma,
it is recognized that autophagy is upregulated in response to
the first-in-line treatment, temozolomide plus radiotherapy
[69]. Autophagy can also be activated by RTK inhibition. For
example, inhibiting EGFR (by erlotinib or ZD6474 treatment)
or PDGFRα/β (by imatinib treatment) have been found to
upregulate autophagy in glioblastoma cell lines [122–124].
The underlying mechanisms of how blocking various stages
of autophagy can affect the survival of glioblastoma and
other types of tumours remain to be further elucidated and
have been reviewed elsewhere [70].10. Manipulating autophagy to improve
glioblastoma treatment
Accumulating pre-clinical studies suggest that autophagy
inhibition enhances the sensitivity of glioblastoma cells to
radiation [125] and chemotherapy including DNA damaging
agents (such as temozolomide), histone deacetylase (HDAC)
inhibitors and RTK targeting molecules [123,124,126–130]
(table 2). Despite the lack of specific chemical regulators of
autophagy, clinical trials targeting autophagy with lysosomal
inhibitors (including CQ and HCQ) during combinational
therapy are currently undergoing aiming to improve the
outcome of currently used anti-cancer treatments [70].
Although there is pre-clinical evidence that suppressing
autophagy may be a promising mechanism to thwartresistance and enhance sensitivity to anti-cancer treatment,
results from clinical trials have provided conflicting evidence
[70]. Early trials reported enhanced survival following sus-
tained CQ co-treatment with chemotherapy and radiotherapy
in glioblastoma patients that had undergone tumour resection
[131,132]. Conversely, in a more recent dose-escalation trial,
administering daily doses of HCQ along with temozolomide
failed to prolong glioblastoma patient survival [133]. The
reason behind the discrepancy between these studies is not
entirely clear but may be attributed to the high doses required
for HCQ to inhibit autophagy following oral uptake, in com-
parison to CQ. This is a limiting factor, as demonstrated by
reduced tolerance and increased toxicity [133]. Furthermore,
the efficacy of CQ/HCQ in suppressing autophagy within
the glioblastoma tumour mass remains questionable due to
the unfeasibility to obtain multiple tumour biopsies from the
brain. Researchers have therefore relied on testing autophagic
activity in circulating peripheral blood mononuclear cells
(PBMCs) from patients [133]. However, this may not reflect
the status of autophagy in the glioblastoma tumour mass,
which is likely to be exposed to lower doses of CQ/HCQ
when compared to the circulating PBMCs (potentially due
to the BBB or the acidic tumour environment) [137,138].
Developing alternative potent inhibitors that target autophagic
degradation may be required to enhance anti-tumour efficacy.
Targeting HDAC activity is an emerging anti-cancer
approach likely to exert its effects through the regulation
of gene expression and chromatin remodelling [139]. Yet, a
royalsocietypublishing.org/journal/rsob
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10recent phase II clinical trial found no significant survival advan-
tage for glioblastoma patients treated with the FDA-approved
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) in
conjunction with temozolomide and radiotherapy [140]. It is
possible that autophagy activation in this setting contributed
to the lack of enhanced survival advantage, which has pre-
viously been demonstrated in glioblastoma cell line cultures
treated with SAHA alone [129] or in combination with
temozolomide [128]. Pharmacological or genetic inhibition of
autophagy in conjunction with SAHA treatment promoted
cell death in cultured glioblastoma cells [129,130]. This has
been promisingly replicated in a mouse model where combin-
ing SAHA or temozolomide with the non-specific autophagy
inhibitor CQ significantly reduced tumour volume of glio-
blastoma cells orthotopically engrafted in C57BL/6 mice
[128]. With this evidence, there is support for redesigning
clinical trials with SAHA and CQ co-treatment to counteract
autophagy-mediated tumour cell survival. Similarly, the clinical
response to RTK inhibition could also potentially benefit
from targeting autophagy. Using CQ to block autophagy
induced by EGFR inhibitors can trigger cell death and
impede tumour growth in mice [123]. In addition, impeding
the last stage of autophagy by bafilomycin A1 treatment
enhances anti-PDGFRα/β cytotoxicity in cell culture [124].
Inhibiting mTOR kinase activity has been used to treat var-
ious cancers. The inactivation of mTORC1 can directly induce
autophagy by releasing the ULK1 complex from its inhibitory
phosphorylation. In the case of glioblastoma, treatment with
rapamycin, which inhibits mTORC1 by limiting its access to
substrates, augments the cytotoxic response of irradiated pri-
mary glioblastoma neurospheres [141] and glioblastoma cells
that were irradiated in combination with genetic silencing of
EGFR [142]. These effects of inhibiting mTORC1 were shown
to be mediated by autophagy activation, whereby blocking
autophagosome formation chemically (by 3-MA treatment)
bypassed the anti-tumour effects of mTORC1 inhibition [141].
Despite promising pre-clinical evidence for using rapamycin
(sirolimus) or its derivative (everolimus) to treat glioblastoma
patients, mTORC1 inhibition has failed to translate to effective
clinical responses when used as a single agent [134] or in com-
bination with EGFR tyrosine kinase inhibitors [135,136]. The
lack of efficacy has been attributed to limited delivery to the
tumourmass [134]. However, amore potent version of rapamy-
cin coupled to an mTOR kinase inhibitor by a polyethylene
glycol linker (RapaLink-1) has revealed glioblastoma tumour
regrowth following preliminary regression in a mouse model,
indicating that tumour cells eventually acquire treatment resist-
ance to the cytotoxic effect of mTOR inhibition [143]. Whether
activated autophagy contributes to the resistance phenotype
needs to be investigated.
The disparity in the role of autophagy during glioblastoma
response to therapy could indicate that the upregulation ofautophagy beyond a specific threshold, for an example during
rapamycin treatment, may cause intracellular stress that
sensitizes cells to death-stimulating signals. Therefore, targeting
autophagy as a means to treat glioblastoma requires careful
investigation and modelling prior to clinical application.11. Conclusion and future perspectives
Numerous findings have described the relevance of autophagy
in tumourigenesis. Autophagy plays a role in maintaining
cellular homeostasis and thereby prevents oncogenic trans-
formation and tumour growth in certain tissues. On the
contrary, it is also appreciated that cell stress-induced auto-
phagy is used by many established tumours to enable
their unconstrained growth in the restrictive tumour environ-
ment. Furthermore, autophagy upregulation in response
to chemotherapy and radiotherapy can lead to treatment resist-
ance by aiding tumour cell survival. To date, evidence from
glioblastoma models indicates that autophagy is involved in
tumour initiation, development and response to treatment.
Yet manipulating autophagy in patients has had limited
success in improving their survival indicating that under-
standing the relevance of autophagy in various aspect of
glioblastoma requires in-depth investigation.
Currently, targeting autophagy in the clinical setting is
limited to a few non-specific inducers and suppressors. For
that reason, mechanistic understanding of autophagy
requires additional research in order to develop novel and
specific modulators. Additionally, it will be key to evaluate
if autophagy dependency of glioblastoma tumour cells is
influenced by molecular subtypes. Determining if a subset
of patients is more likely to benefit from autophagy modu-
lation could lead to personalized treatment and potentially
better outcomes. Finally, given the impact of autophagy in
both tumour and stromal cells, it would be important to
employ whole-body genetic modulation of autophagy in
pre-clinical studies in order to closely mimic its therapeutic
targeting. It is possible that modulating autophagy in
tumour and stromal cells may give opposing impact on
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